CGEN - Earnings announcements

COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026Gilead-partnered GS-0321 Phase 1 trial continues to progress as plannedSolid financial position with cash runway expected to fund operations into 2029HOLON, Israel, May 18, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunoth

HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the foll

Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029Enhanced leadership team with Dr. Eran Ophir appointed President and CEO and Dr. Anat Cohen-Dayag transitioned to Executive ChairAdvanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprintPresented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectivelyOn track to have MAIA-ovarian interim analysis in Q1 2027Partner AstraZeneca reported promising Phase 2 rilvegost

HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is l

COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trialEnrolling patients in the U.S., Israel and France in the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in patients with platinum sensitive ovarian cancer with interim analysis now estimated in Q1 2027SITC 2025 – Compugen presented Phase 1 trial design for GS-0321 (COM503), licensed to GileadPartner AstraZeneca shared promising rilvegostomig results from two Phase 2 trials, one in NSCLC and one in bladder cancer at ESMO 2025Solid financial position with refined cash runway expected to fund operations into Q3 2027HO

HOLON, Israel, Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that the Company will release its third quarter 2025 financial results on Monday November 10, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is l

First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025Pooled analysis from three previously reported Phase 1 trials of COM701 in platinum resistant ovarian cancer to be presented at ESMO 2025Recruitment ongoing in Phase 1 trial of GS-0321 (COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca plans to share updated rilvegostomig data from Phase 2 ARTEMIDE-01 in NSCLC and first data from Phase 2 TROPION-PanTumor03 in bladder cancer at ESMO 2025Solid financial position with cash runway expected to fund operations into 2027HOLON, Israel, Aug. 6, 2025 /PRNewswire/ -- 

HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which i

Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASCOSolid financial position with cash runway expected to fund operations into 2027Key leadership transitions to take effect in September 2025HOLON, Israel, May 19, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage ca

HOLON, Israel, May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following

In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combina

HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.  Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following lin

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the CompanyPlans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commercial opportunityOn track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024Partner AstraZeneca reported encouraging rilvegostomig data at WCLC and ESMO 2024

HOLON, ISRAEL, Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). This data and additional clinical data will be presented by Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecolog

HOLON, Israel, Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. As part of the update, management will discuss Compugen's data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-10, 2024. To access the live conference call by telepho

FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the CompanySolid balance sheet with cash runway expected to fund operations into 2027HOLON, Israel, Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a

HOLON, Israel, July 23, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the

Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meetingOn track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 study well advancedPartner, AstraZeneca, progressed rilvegostomig into second Phase 3 trial in nonsquamous NSCLC; Compugen eligible for development milestone payments for this second indicationSolid balance sheet with extended cash runway expected to fund operations into 2027HOLON, Israel, May 20, 2024 /PRNe

HOLON, ISRAEL, May 6, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live w

Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilitiesCatalyst rich 2024 expected with multiple data readouts and updates planned from Compugen's diversified portfolioSolid balance sheet with extended cash runway expected to fund operations into 2027HOLON, Israel, March 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2023 and provided a corporate update. "Our accomplishments in 2023 position us well for an exciti

HOLON, Israel, Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreementHOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types. Conference Call Details To access the live c

Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer; initial findings expected by year end Data from multiple studies planned to be presented by the end of the year:     - New data from metastatic breast cancer study evaluating COM701+ nivolumab       - New translational data and initial biomarker data from platinum resistant ovarian cancer studies evaluating COM701 + nivolumab ± BMS anti-TIGIT      - Longer-term patient follow up from platinum resistant ovarian cancer study evaluating COM701 +  nivolumab + BMS anti-TIGIT      - New data from COM503 lead p

HOLON, Israel, July 24, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter financial results on Monday, August 7, 2023, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live w

On track to deliver initial findings from studies with the triple blockade of PVRIG, TIGIT and PD-1 in patients with MSS CRC and platinum resistant ovarian cancer by end of 2023New pre-clinical data presented at CIMT for COM503, a high affinity anti-IL-18BP antibody approach differentiated from cytokine therapeutic approachesCash balance of $74.3 million with runway through potential key milestones expected into at least end of 2024Company hosting DNAM-1 axis virtual investor event with KOL Drew Pardoll on Tuesday, May 23, 2023 at 12pm ET, registration on company websiteHOLON, Israel, May 15, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy

HOLON, Israel, May 1, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2023 financial results on Monday, May 15, 2023, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live w

On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG, COM701, potential best-in-class anti-TIGIT, COM902 and pembrolizumabInitial findings from both triple combination studies expected by end of 2023Approximately $83.7 million in cash, as of end of 2022, expected to fund operations at least through the end of 2024HOLON, Israel, Feb. 27, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and pioneer in computational target discovery, today reported financial results for the fou

HOLON, Israel, Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023, before the U.S. financial markets open.  Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally.  The call will be available via live webcast through Compugen's website, located at the following link, Followin

COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed partial responses (overall response rate 20% (n=20) triple study, 10% (n=20) dual study and disease control rate (45%) for both), supported by immune activation with a favorable safety and toxicity profileThree of the patients responded to triplet therapy for at least 9 months as of the data cut-off date and all four triplet responders continue treatmentAnti-tumor activity with confirmed partial responses reported in diverse histologies, with majority (5 out of 6 responders in the two combinations) in the hardest to treat high-grade serous adenoca

At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum resistant ovarian cancer and was well tolerated, with all responders remaining on therapyLonger follow up data will be included in the posters available on ESMO Immuno-Oncology Congress 2022 (ESMO-IO) virtual platform on December 6, 2022Management will discuss the preliminary data to be presented as posters at ESMO-IO during an investor call planned for Wednesday, December 7, 2022, at 8:30 am ETHOLON, Israel, Dec. 1, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer

New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor microenvironment following combination of COM701 and nivolumab in metastatic MSS-CRC patients. Further clinical evaluation of COM701 as a triple combination with an anti-PD-1 and COM902 will be pursued.New encouraging preliminary clinical data from dual and triple combination of COM701+nivolumab ± BMS-986207 (anti-TIGIT) in platinum resistant ovarian cancer patients to be presented at ESMO-IO. Further clinical evaluation will be pursued in this indication.Solid balance sheet, with cash runway expected at least through the end of 2024.HOLON, Israel,

HOLON, Israel, Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open.  Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. As part of the update, management will discuss Compugen's data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-12, 2022. To access the live conference call by telephone, please dial 1-866-744-539

Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902Focus on MSS-CRC and NSCLC expected to provide highest probability of success and support future path to registrationFocused development plan results in strategic decision to wind down Phase 1 cohort expansion studies resulting in the conclusion of collaboration with Bristol Myers SquibbMost advanced preclinical program with first-in-class potential entering pre-IND enabling studiesExtended cash runway expected to last through the end of 2024HOLON, Israel, Aug. 4, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target di

HOLON, Israel, July 21, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its second quarter financial results on Thursday, August 4, 2022, before the U.S. financial markets open.  Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live webcast, a

HOLON, Israel, May 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its first quarter 2022 financial results on Monday, May 16, 2022, before the U.S. financial markets open. Management will not host a conference call to accompany this release. Management plans to provide a corporate update at two global investor healthcare conferences in June 2022. Details of the planned presentations will be provided closer to the events. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable pred

HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today reported financial results for the fourth quarter ended December 31, 2021, and full year 2021 and provided an update on recent Company highlights. "Compugen made excellent progress in 2021. As the leader in the DNAM-1 axis we believe that blocking its complementary pathways has the potential to be a game changer in treating inflamed as well as less inflamed tumors, in patients who do not respond to available therapies. I am particularly excited about the translational data we presented across all

HOLON, Israel, Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally.  The call will be available via live webcast through Compugen's website, located at the following link. Followi

- COM701, Opdivo® and BMS-986207, triple combination dose escalation Phase 1/2 data being presented at 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) clears the path to studies in select biomarker informed tumor types - COM902 monotherapy dose escalation Phase 1 data being presented at SITC shows favorable safety profile, Phase 1 cohort expansion in combination with COM701 currently enrolling - COM701 translational data being presented at SITC support the differentiation of PVRIG compared to TIGIT and PD-1 as a novel checkpoint in the DNAM axis - Strong cash position with $20 million equity investment from Bristol Myers Squibb and $6 million milestone payment from Ast

HOLON, Israel, Oct. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021, before the U.S. financial markets open.  Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. As part of the update, management will also discuss Compugen's data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 10-14, 2021.  The eposters will be available on Friday November 12, 2021. To access

HOLON, Israel, July 28, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2021. "Our continued execution in the clinic, which includes the recent initiation of three clinical studies, further strengthens Compugen's leadership position in the DNAM axis space," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "These new studies expand our comprehensive evaluation of the DNAM axis and leave us uniquely positioned as the only company, in a clinical setting, evaluating anti-PVRIG, anti-TIGIT and anti-PD-1 combinati